Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

NZ sharemarket rises on back of positive news
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
The Warehouse’s plan to come back ‘with a vengeance’
Retail

The Warehouse’s plan to come back ‘with a vengeance’

Executives face tough questions at the retailer’s AGM.

Victoria Young 22 Nov 2024
Wellington's blue sky boondoggle
Infrastructure

Pattrick Smellie: Wellington's blue sky boondoggle

Is the capital's airport serious, or is Infratil just trying to pump value?

Pattrick Smellie 22 Nov 2024